TMED8 Inhibitors
TMED8 inhibitors encompass a range of compounds that exert their inhibitory effects through disruption of intracellular transport and membrane trafficking pathways. For instance, compounds that perturb the structure and function of the Golgi apparatus, such as those affecting the anterograde transport from the endoplasmic reticulum to the Golgi, or altering intracellular pH, can indirectly inhibit the functional activity of TMED8. Given TMED8's involvement in ER-Golgi trafficking, the inhibition of related secretory pathways impacts its role in vesicular trafficking. Moreover, agents that destabilize the cellular cytoskeleton, including actin and microtubule networks, interrupt the vesicular transport processes essential for TMED8's function. By preventing the polymerization of cellular cytoskeletal components or inhibiting factors involved in vesicle scission from the Golgi, these compounds effectively reduce the ability of TMED8 to maintain vesicle structure and transport.
In addition, several small molecule inhibitors target proteins that are upstream or integral to the vesicle formation and trafficking process, thereby exerting an indirect inhibitory effect on TMED8. For example, compounds that disrupt the recruitment of coat proteins necessary for vesicle formation or those that inhibit the cytoskeletal dynamics and exocyst complex components essential for vesicle tethering impede TMED8-dependent trafficking. Other inhibitors workby interfering with the formation of clathrin-coated vesicles or altering cholesterol homeostasis, thereby affecting the overall membrane dynamics critical for vesicle formation and transport.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
This compound disrupts the Golgi apparatus structure and function, leading to a blockade in the anterograde transport from the endoplasmic reticulum (ER) to the Golgi. Given TMED8's role in ER-Golgi trafficking, Brefeldin A's action results in the inhibition of TMED8's function in transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that alters intracellular pH and disrupts Golgi function. It interferes with secretory pathways, including the transport of proteins from the ER to the Golgi, indirectly inhibiting TMED8's role in vesicular trafficking. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
This agent destabilizes microtubules, thereby interrupting vesicular transport processes, which are essential for TMED8-mediated trafficking between the ER and the Golgi apparatus, leading to its inhibition. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
An inhibitor of actin polymerization, Cytochalasin D impedes actin-dependent intracellular transport, which is crucial for TMED8's function in maintaining vesicle structure and transport. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
A specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), Golgicide A disrupts ARF1-mediated recruitment of coat proteins, thereby inhibiting vesicle formation and indirectly affecting TMED8-mediated transport. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
A small molecule that inhibits dynamin, Dynasore disrupts clathrin-mediated endocytosis and vesicle scission from the Golgi, indirectly impacting TMED8's role in vesicle formation and trafficking. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 4 | |
A small molecule inhibitor of exocyst complex component Sec10, Exo1 disrupts the exocyst complex, which is involved in tethering vesicles to the plasma membrane, indirectly leading to inhibition of TMED8-dependent trafficking. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
A small molecule inhibitor of cytohesin, SecinH3 impedes ARF activation, which is necessary for coat protein recruitment to vesicles. This inhibition affects vesicle formation, thereby indirectly inhibiting TMED8's role in vesicular trafficking. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
As a potent inhibitor of Cdc42, a small GTPase involved in actin cytoskeleton organization, ML 141 disrupts cytoskeletal dynamics, indirectly impeding TMED8-dependent vesicular transport processes. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
This compound is an inhibitor of formin-mediated actin polymerization, which is essential for the maintenance of cytoskeletal integrity and vesicle transport, indirectly inhibiting TMED8's function in trafficking. | ||||||